Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (785)	10/31/2000 1:50:06 PM
From: nigel bates	Respond to of 1475

Oct 31 (Reuters) - British biotechnology company ReNeuron Holdings Ltd, a specialist in manipulating neural stem cells as a treatment for brain damage, said on Tuesday it planned to price its initial public offering next week. Chief Executive Martin Edwards told Reuters the offering would close on November 9 with first trading on the London Stock Exchange's junior Alternative Investment Market scheduled to start on November 16. The company is looking to raise 15-20 million pounds via a placing of ordinary shares, valuing the business at 60-75 million pounds....